2030 Stock Overview
Daan Gene Co., Ltd. researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Daan Gene Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.41 |
| 52 Week High | CN¥15.60 |
| 52 Week Low | CN¥6.66 |
| Beta | 0.58 |
| 1 Month Change | -10.72% |
| 3 Month Change | -13.94% |
| 1 Year Change | -52.07% |
| 3 Year Change | -63.64% |
| 5 Year Change | 11.75% |
| Change since IPO | 698.95% |
Recent News & Updates
Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 05
Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)
Mar 25Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Mar 06Shareholder Returns
| 2030 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 0.1% | -0.2% | -0.3% |
| 1Y | -52.1% | -25.2% | -14.6% |
Return vs Industry: 002030 underperformed the CN Biotechs industry which returned -24.8% over the past year.
Return vs Market: 002030 underperformed the CN Market which returned -14.4% over the past year.
Price Volatility
| 2030 volatility | |
|---|---|
| 2030 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002030 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002030's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,968 | Luo Huang | www.daangene.com |
Daan Gene Co., Ltd. researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables. The company offers fluorescence quantitative PCR products, enzyme-linked immunoassay products, instrument products, and scientific research service products. It also provides medical examination, and health consultation and management services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services.
Daan Gene Co., Ltd. Fundamentals Summary
| 2030 fundamental statistics | |
|---|---|
| Market cap | CN¥10.40b |
| Earnings (TTM) | CN¥104.66m |
| Revenue (TTM) | CN¥1.18b |
99.4x
P/E Ratio8.8x
P/S RatioIs 2030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2030 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.18b |
| Cost of Revenue | CN¥801.12m |
| Gross Profit | CN¥379.78m |
| Other Expenses | CN¥275.12m |
| Earnings | CN¥104.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.075 |
| Gross Margin | 32.16% |
| Net Profit Margin | 8.86% |
| Debt/Equity Ratio | 3.6% |
How did 2030 perform over the long term?
See historical performance and comparison